Aman Chauhan: Our Investigator initiated study of SVV plus Ipi-Nivo is all set to start
Aman Chauhan, the leader of Neuroendocrine Cancer Program at Sylvester Comprehensive Cancer Center, posted on X:
“What a way to celebrate birthday. Got an amazing gift from FDA. Our Investigator initiated study of combination SVV plus Ipi-Nivo is all set to start. We will be enrolling high grade neuroendocrine cancer patients, a critical unmet need.
5 year of effort finally bearing fruits!!
Suggested reading: our work on SVV and its biomarker over the years.
- Abstract 6851: The genomic, transcriptomic, and immunologic landscape of TEM8 (ANTXR1) in neuroendocrine neoplasms (NENs)
- The genomic, transcriptomic, and immunologic landscape of TEM8 (ANTXR1) in small-cell lung cancer (SCLC).
- Oncolytic Seneca Valley Virus (SVV-001) Overcomes Checkpoint Inhibitor Resistance and Demonstrates a Systemic Anti-tumor Response in a Syngeneic Tumor Model
- TEM8 in Oncogenesis: Protein Biology, Pre-Clinical Agents, and Clinical Rationale
- Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics
- Clinical Application of Oncolytic Viruses: A Systematic Review.“
Dr. Aman Chauhan is the leader of Neuroendocrine Cancer Program at Sylvester Comprehensive Cancer Center and focuses on treating neuroendocrine tumors (NETs), including carcinoid tumors and high-grade neuroendocrine carcinomas. He is the national principal investigator for several investigator-initiated neuroendocrine cancer theranostics clinical trials. Dr. Chauhan serves on AJCC and ASCO NET guideline committees, and is an active member of the NANETS communication committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023